MK
Mette Kirstine Agger
Angel InvestorActiveMette Kirstine Agger is Managing Partner of Lundbeckfond Ventures and has over 20 years of broad international leadership experience within ...
33
Investments
0
Exits
—
AUM
0.0%
Exit Rate
Get contact info, warm intros & fit scores
Sign up to unlock emails, Signal intro paths, and personalized fit analysis for Mette Kirstine Agger.
Investment Thesis & Strategy
As an angel investor, Mette Kirstine Agger invests in various stages across a broad range of industries, likely seeking promising early-stage companies with high growth potential.
Investment Activity
Deals per year over the last 7 years
2
20141
20154
20161
20170
20180
20191
2020Portfolio Companies
Selected investments from their portfolio of 33 companies
V
VHSquared
Biotech · Seed, 0
T
Tiburio Therapeutics
Biotech · Seed, 0
D
DBV Technologies
Biotech · Series C+, 0
L
LEXEO Therapeutics
Biotech · Series A, 2020
S
SNIPR Biome
Other · , 2017
A
AlloCure
Biotech · Series A, 2016
V
VarmX
Biotech · Series A, 2016
I
Imara
Biotech · Series B, 2016
I
IO Biotech
Biotech · Series A, 2016
R
Reneo Pharmaceuticals
Biotech · Series B, 2015
V
Vtesse
Biotech · Series B, 2014
A
Amplyx Pharmaceuticals
Biotech · Series A, 2014
Frequently Asked Questions
Mette Kirstine Agger focuses on Pre-seed, Seed stage investments.